News
Phase 3 trial tests a sprayed medicine for nerve pain in diabetes
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A phase 3 trial registered on ClinicalTrials.gov on 5 October 2026 will test YJ001, a spray developed by Zhejiang Hanmai Pharmaceutical Technology, in adults with painful diabetic peripheral neuropathy. The registration describes a two-part study: a randomised, double-blind, double-dummy, multi-centre phase 3 comparison against an approved reference medicine and placebo in about 400 participants, followed by an open-label single-arm part. The record lists a planned start of August 2026 and posts no results yet.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — trial registry record (public domain in the United States); our own summary and a link to the registry record, data as posted on 6 October 2026.